PMID- 12903626
OWN - NLM
STAT- MEDLINE
DCOM- 20030905
LR  - 20171213
IS  - 0300-8916 (Print)
IS  - 0300-8916 (Linking)
VI  - 89
IP  - 4 Suppl
DP  - 2003 Jul-Aug
TI  - [Adjuvant adoptive immunotherapy in patients with stage III and resected stage IV 
      melanoma: a pilot study].
PG  - 298-300
AB  - Adoptive immunotherapy trials with tumor infiltrating lymphocytes (TIL) and 
      interleukin-2 (IL-2) were carried out in the treatment of advanced melanoma with 
      a 34% of overall responses (OR). However, theoretically it should be of greater 
      benefit as adjuvant therapy, especially in high-risk stages (stage III and 
      resected stage IV). In a pilot study, 22 patients (aged 23-72 years) with stage 
      III-IV melanoma who underwent radical metastasectomy were reinfused with TIL 
      cultivated and expanded in vitro with IL-2 from surgically removed metastases. 
      IL-2 (starting dose 12 x 10(6) IU/m2) was co-administered as a continuous 
      infusion according to West's scheme. A total of 8/22 (36.3%) patients were 
      disease-free (DF) at a median follow-up of 5 years. DF survival (DFS) and overall 
      survival (OS) in the remaining 14 patients were 44% and 37% and 52% and 45% at 2 
      and 3 years, respectively. The CNS was the only site of disease recurrence in 57% 
      of patients who relapsed. DF patients received a higher median dose of IL-2 than 
      those who progressed (total dose 110 x 10(6) vs 86 x 10(6) IU/m2, respectively). 
      The progressive reduction in IL-2 dosage allowed all patients to complete 
      treatment without permanent grade 4 toxicity. The effects of tumor 
      immunosuppression in lymphocytes inside the tumor (TCR z and e chains, p56lck, 
      FAS and FAS-ligand) confirmed that the potential function of TIL, immunodepressed 
      at the time of metastasectomy, was significantly restored after in vitro, culture 
      with IL-2. Adjuvant adoptive immunotherapy with TIL and IL-2 seems to improve DFS 
      and OS, in comparison with literature data. Further studies are required to 
      determine its role in the adjuvant treatment of patients with high-risk melanoma.
FAU - Verdecchia, G M
AU  - Verdecchia GM
AD  - Istituto Oncologico Romagnolo (IOR), Forli.
FAU - Ridolfi, L
AU  - Ridolfi L
FAU - Ridolfi, R
AU  - Ridolfi R
FAU - Riccobon, A
AU  - Riccobon A
FAU - Bertagni, A
AU  - Bertagni A
FAU - Vagliasindi, A
AU  - Vagliasindi A
FAU - Petrini, M
AU  - Petrini M
FAU - Stefanelli, M
AU  - Stefanelli M
FAU - Milandri, C
AU  - Milandri C
FAU - Amadori, D
AU  - Amadori D
LA  - ita
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
TT  - Adjuvant adoptive immunotherapy in patients with stage III and resected stage IV 
      melanoma: a pilot study.
PL  - United States
TA  - Tumori
JT  - Tumori
JID - 0111356
RN  - 0 (Interleukin-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cells, Cultured/drug effects/transplantation
MH  - Central Nervous System Neoplasms/secondary
MH  - Combined Modality Therapy
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - *Immunotherapy, Adoptive
MH  - Interleukin-2/pharmacology
MH  - Lung Neoplasms/secondary
MH  - Lymphatic Metastasis
MH  - Lymphocytes, Tumor-Infiltrating/drug effects/*transplantation
MH  - Male
MH  - Melanoma/immunology/secondary/surgery/*therapy
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Pilot Projects
MH  - Skin Neoplasms/immunology/secondary/surgery/*therapy
MH  - Survival Analysis
MH  - Treatment Outcome
EDAT- 2003/08/09 05:00
MHDA- 2003/09/06 05:00
CRDT- 2003/08/09 05:00
PHST- 2003/08/09 05:00 [pubmed]
PHST- 2003/09/06 05:00 [medline]
PHST- 2003/08/09 05:00 [entrez]
PST - ppublish
SO  - Tumori. 2003 Jul-Aug;89(4 Suppl):298-300.